| abstract |
A stable pharmaceutical composition of erythropoietin (EPO), consisting of: a. a therapeutically effective amount of EPO b. a pharmaceutically acceptable pH regulatory system, and c. polyvinylpyrrolidone (PVP) and optionally d. an isotonifying agent and / or e. one or more pharmaceutically acceptable excipients selected from the group consisting of polyols, hydroxypropylcellulose, methylcellulose, macrogol esters and ethers, glycol and glycerol esters, and amino acids, optionally to poloxamer or a polysorbate as an additional stabilizer. |